Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.

Conversely, no significant differences were observed for cladribine- or IFN-β-treated patients, likely due to the small sample size; however, an increasing trend of anti-RBD-IgG titers was found.

also in 63,971 other papers

Similar results were found within the CD8 + T-cell compartment for TNF-α (p=0.034) and IL-2 (p<0.0001), whereas the IFN-γ-specific CD8 + T cells showed a trend of reduction, although not significant ( figure 2D ).

also in 53,322 other papers